Therefore, disruptions in these promoter configurations can result in severe metabolic and oncogenic consequences, the relationship between the SSR4 gene and the IDH genes in ESCC needs to be further explored, providing novel insights of potential therapeutic targets. Here, IDH2 is linked to esophageal squamous cell carcinoma.